← Back to Screener
Entera Bio Ltd. Ordinary Shares (ENTX)
Price$1.34
Favorite Metrics
Price vs S&P 500 (26W)-60.45%
Price vs S&P 500 (4W)5.82%
Market Capitalization$62.47M
All Metrics
Book Value / Share (Quarterly)$0.33
P/TBV (Annual)2.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-31.78%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-38.16%
Gross Margin (TTM)4.04%
Net Profit Margin (TTM)-4525.11%
EPS (TTM)$-0.24
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)-5.49%
EPS (Annual)$-0.25
ROI (Annual)-118.08%
Gross Margin (Annual)4.97%
Net Profit Margin (5Y Avg)-4999.23%
Cash / Share (Quarterly)$0.19
ROA (Last FY)-101.61%
Revenue Growth TTM (YoY)25.25%
EBITD / Share (TTM)$-0.24
ROE (5Y Avg)-103.66%
Operating Margin (TTM)-4522.87%
Cash Flow / Share (Annual)$-0.18
P/B Ratio4.10x
P/B Ratio (Quarterly)5.76x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)241.70x
Net Interest Coverage (TTM)-407.33x
ROA (TTM)-63.36%
EPS Incl Extra (Annual)$-0.25
Current Ratio (Annual)7.63x
Quick Ratio (Quarterly)10.73x
3-Month Avg Trading Volume0.21M
52-Week Price Return-27.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.88
P/S Ratio (Annual)345.16x
Asset Turnover (Annual)0.02x
52-Week High$3.22
Operating Margin (5Y Avg)-5048.91%
EPS Excl Extra (Annual)$-0.25
CapEx CAGR (5Y)-40.43%
26-Week Price Return-51.70%
Quick Ratio (Annual)7.63x
13-Week Price Return-21.47%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.83x
Enterprise Value$53.9
Revenue / Share Growth (5Y)-24.68%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-20.80%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5263.54%
Cash / Share (Annual)$0.22
3-Month Return Std Dev113.03%
Gross Margin (5Y Avg)18.91%
Net Income / Employee (TTM)$-1
ROE (Last FY)-118.08%
Net Interest Coverage (Annual)-445.45x
EPS Basic Excl Extra (Annual)$-0.25
Receivables Turnover (TTM)5.90x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.24
Receivables Turnover (Annual)2.87x
ROI (TTM)-71.93%
P/S Ratio (TTM)280.15x
Pretax Margin (5Y Avg)-4977.17%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.63
Price vs S&P 500 (52W)-62.37%
Year-to-Date Return-34.02%
5-Day Price Return14.29%
EPS Normalized (Annual)$-0.25
ROA (5Y Avg)-87.81%
Net Profit Margin (Annual)-5271.27%
Month-to-Date Return15.32%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.25
Operating Margin (Annual)-5295.58%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-103.66%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)5.34x
P/B Ratio (Annual)9.66x
Pretax Margin (TTM)-4518.83%
Book Value / Share (Annual)$0.21
Price vs S&P 500 (13W)-24.34%
Beta1.59x
Revenue / Share (TTM)$0.00
ROE (TTM)-71.93%
52-Week Low$0.91
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ENTXEntera Bio Ltd. Ordinary Shares | 280.15x | 25.25% | 4.04% | — | $1.34 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Entera Bio is a clinical-stage biopharmaceutical company developing orally administered peptide therapeutics for chronic conditions, including osteoporosis and hypoparathyroidism. Its lead candidates are first-in-class mini tablet formulations of synthetic PTH (1-34) with tailored pharmacokinetic profiles, designed to offer patients a more convenient alternative to current injectable therapies.